Managlinat dialanetil

DB05518InvestigationalSmall molecule

CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.

Mechanism: In type 2 diabetes, the liver produces excessive amounts of glucose through the gluconeogenesis (GNG) pathway and consequently is partly responsible for the elevated glucose levels characteristic of the disease. CS-917 targets the AMP binding site of fructose 1,6-bisphosphatase (FBPase), inhibiting the GNC pathway.
Curator reviewed
Primary indication: Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
Formula / weight: C₂₁H₃₃N₄O₆PS · 500.55 g/mol (avg)
Code names: CS-917 · MB-06322 · R 132917

Resolves to

Compound

Structure

InChIKeyBYKBUQDQTLDNLE-KBPBESRZSA-NSMILES[H][C@@](C)(NP(=O)(N[C@@]([H])(C)C(=O)OCC)C1=CC=C(O1)C1=C(CC(C)C)SC(N)=N1)C(=O)OCC

Targets

What you can answer from here — as of January 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Managlinat dialanetil, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.